Clinical Trials Logo

Brain Cancer clinical trials

View clinical trials related to Brain Cancer.

Filter by:

NCT ID: NCT06322342 Recruiting - Multiple Sclerosis Clinical Trials

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

This Phase 2 trial will assess the safety, tolerability, efficacy, imaging pharmacodynamics, and pharmacokinetics of RVP-001, a novel manganese-based MRI contrast agent, at three escalating dose levels. RVP-001 will be administered as a single IV bolus to subjects with known gadolinium-enhancing central nervous system (CNS) lesions (for example stable brain tumor or multiple sclerosis) who have recently had a gadolinium-based contrast agent (GBCA)-enhanced MRI of the brain.

NCT ID: NCT06180460 Recruiting - Clinical trials for Metastatic Breast Cancer

CALM: Managing Distress in Malignant Brain Cancer

Start date: November 10, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM), compared to treatment as usual (TAU) in those with malignant brain cancer diagnoses.

NCT ID: NCT06168825 Active, not recruiting - Breast Cancer Clinical Trials

Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention

MOM
Start date: January 17, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to learn if the Mind Over Matter (MOM) Intervention, a 5-week group program, can help Black and African American women deal with the fears, worries and sadness that often accompany cancer diagnosis and treatment. The main question this study aims to answer is: • Whether the MOM Intervention is feasible and acceptable among Black and African American women. We would also like to find out if: - The MOM Intervention decreases anxiety, depression and physical symptom severity for Black and African American women. - The MOM Intervention is culturally and linguistically appropriate, and identify barriers, strengths, and areas of improvement. Participants will: - Attend a Pre-Program Orientation - Attend 5 weekly MOM Sessions - Complete 2 questionnaires (one will be given before the first MOM Session begins, and the other will be given after the last MOM Session) Participants also have the choice to attend an optional Focus Group, which will be offered after the last MOM Session. Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits.

NCT ID: NCT06058988 Recruiting - Glioblastoma Clinical Trials

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Start date: September 22, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

NCT ID: NCT06048094 Recruiting - Brain Metastases Clinical Trials

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

FACILITATE
Start date: April 11, 2024
Phase: Phase 1
Study type: Interventional

This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.

NCT ID: NCT05979064 Recruiting - Glioblastoma Clinical Trials

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

Start date: April 4, 2023
Phase: N/A
Study type: Interventional

This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

NCT ID: NCT05961111 Recruiting - Breast Cancer Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

Start date: June 24, 2023
Phase: Early Phase 1
Study type: Interventional

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

NCT ID: NCT05954858 Recruiting - Glioblastoma Clinical Trials

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

Start date: June 29, 2023
Phase: N/A
Study type: Interventional

This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS).

NCT ID: NCT05947149 Recruiting - Clinical trials for Head and Neck Cancer

HRQoL in Patients With Solid Tumors Treated With Hadrontherapy

HadroQoL
Start date: March 27, 2023
Phase:
Study type: Observational

The Quality of Life of patients treated with hadrontherapy is still limited. Two cohorts are established, they will be receiving specific standardized questionnaires to be evalutaed in their results.

NCT ID: NCT05943262 Recruiting - Brain Tumor Clinical Trials

Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The research aims to develop a novel pathological technology, including rapid whole-mount tissue H&E & IHC staining protocol and high-resolution nonlinear optical microscopy imaging system, to intraoperatively assess brain tumor grade, types and other biological parameters.